Revolution Medicines Inc (RVMD NASDAQ) stock market data APIs
$79.0752
-0.8(-1%)
as of December 12, 2025
Try our APIs with
free plan!
Revolution Medicines Inc Financial Data Overview
Price chart is built with
Anychart
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C). The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; RMC-5552, a selective inhibitor of mTORC1 signaling in tumors, which is in phase 1 clinical trial; and RMC-5845 that targets SOS1. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Prev. Close
79.0752
Open
78.2734
High
80.751
Low
77.7554
52 wk Range
29.17-81.4865
Market Cap
15 257 M
Shares Outstanding
193 M
Revenue
742 K
EPS
-1.61
Beta
0.959
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Revolution Medicines Inc (top by weight)
Ticker
100-day Price Change
Weight
W311.XETRA
HAN-GINS Indxx Healthcare Megatrend Equal Weight UCITS ETF - Accumulating
0.56
(8.87%)
4.53
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Revolution Medicines Inc data using free add-ons & libraries
Get Revolution Medicines Inc Fundamental Data
Revolution Medicines Inc Fundamental data includes:
- Net Revenue: 742 K
- EBITDA: -1 029 836 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-05
- EPS/Forecast: -1.41
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Revolution Medicines Inc News
New
FDA Breakthrough Status For Daraxonrasib Might Change The Case For Investing In Revolution Medicines (RVMD)
Revolution Medicines has recently advanced daraxonrasib, its oral multi-selective RAS(ON) inhibitor, into a Phase III trial for metastatic pancreatic ductal adenocarcinoma and, in June 2025, received ...
Pancreatic Cancer Market Set to Expand During the Forecast Period (2025-2034) as Precision Medicine and Immunotherapy Transform Treatment Landscape | DelveInsight
The total pancreatic cancer market size is expected to increase in the 7MM during the forecast period, driven by ongoing clinical research and the development of better diagnostic tools, which may imp...
Delphia Therapeutics Appoints Leading Cancer Expert Steve Kelsey, M.D., to Board of Directors
CAMBRIDGE, Mass., December 09, 2025--(BUSINESS WIRE)--Delphia Therapeutics, Inc. (Delphia), a biopharmaceutical company pioneering an innovative new area of cancer biology – activation lethality –...
Revolution Medicines (RVMD) Up 27.9% Since Last Earnings Report: Can It Continue?
It has been about a month since the last earnings report for Revolution Medicines, Inc. (RVMD). Shares have added about 27.9% in that time frame, outperforming the S&P 500. Will the recent positive t...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
